Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?-Reference-Cited by-同舟云学术

Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?

Published:2023-09-09 Issue:1 Volume:44 Page:142-145
ISSN:0743-8346
Container-title:Journal of Perinatology
language:en
Short-container-title:J Perinatol

Author:

Lure Allison C.^ORCID,Sánchez Pablo J.^ORCID,Slaughter Jonathan L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology,Pediatrics, Perinatology and Child Health

Link

https://www.nature.com/articles/s41372-023-01769-3.pdf

Reference20 articles.

1. Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386:1615–26.

2. US Food and Drug Administration. Synagis; 2021. p. 1–15.

3. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620–38.

4. O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy native American infants: a phase 3 randomized double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15:1398–408.

5. Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W. Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants. Pharmacoecon Open. 2018;2:53–61.